Analysed FIBROBIOLOGICS INC (FBLG:NASDAQ) News Sources
FibroBiologics Announces Release of CYWC628 Drug Product for Phase 1/2 Diabetic Foot Ulcer Clinical Trial
04-05-2026
yahoo.com
FibroBiologics Reports Preclinical Data Showing Fibroblast Spheroids May Actively Reprogram the Burn Wound Environment to Drive Healing and Reduce Scarring
04-05-2026
yahoo.com
FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
18-05-2026
yahoo.com
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
22-05-2026
yahoo.com
Is FibroBiologics, Inc. (FBLG) Advancing Toward a Breakthrough Psoriasis Treatment With CYPS317 Data?
02-06-2026
yahoo.com
EXCLUSIVE: FibroBiologics Doses First Patients In Diabetic Foot Ulcers Clinical Trial
03-06-2026
yahoo.com
FibroBiologics Announces First Patients Dosed in Phase 1/2 Clinical Trial Evaluating CYWC628 for the Treatment of Diabetic Foot Ulcers
03-06-2026
yahoo.com
What is the current price of FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The current price of FIBROBIOLOGICS INC (FBLG:NASDAQ) is $0.931.
FIBROBIOLOGICS INC (FBLG:NASDAQ) absolute price change since previous trading day?
The absolute price change of FIBROBIOLOGICS INC (FBLG:NASDAQ) since the previous trading day is $-0.033.
FIBROBIOLOGICS INC (FBLG:NASDAQ) percentage price change since previous trading day?
The percentage price change of FIBROBIOLOGICS INC (FBLG:NASDAQ) since the previous trading day is -3.4232%.
What is the most recent average sentiment score for FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The most recent average sentiment score for FIBROBIOLOGICS INC (FBLG:NASDAQ) is 78 out of 100.
What is the most recent average sentiment for FIBROBIOLOGICS INC (FBLG:NASDAQ)?
The most recent sentiment for FIBROBIOLOGICS INC (FBLG:NASDAQ) is .
SEC-8K** Filing Available For FIBROBIOLOGICS INC (FBLG:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.